(TheNewswire) Toronto, Ontario - TheNewswire - September 15, 2023 – Tantalex Lithium Resources Corp. (CSE:TTX) – (FSE:DW8) – (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to announce a non-brokered private placement consisti...Read More
(NewsDirect) Tantalex Lithium CEO Eric Allard joined Steve Darling from Proactive to share news the company has announced a significant development for the company. The company has reached a term sheet agreement with Glencore International AG for a marketing offtake agreement related to lithium pro...Read More
VANCOUVER, BC / ACCESSWIRE / September 11, 2023 / The Watchlist by The Market Herald has announced the release of new interviews with Ciscom Corp and Tantalex Lithium Resources discussing their latest news.The Watchlist by The Market Herald provides investors with a quick snapshot of what th...Read More
(TheNewswire) KEY HIGHLIGHTS Marketing Offtake Agreement for Spodumene concentrate (SC6) to be produced from the Manono Lithium Tailings Project located in Manono, Tanganyika province, in the DRC. USD 5M staged secured convertible financing facility upon issuance of acceptable Pre...Read More
TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), is a clinical stage pharmaceutical company focused on the research, development and commercialization of light activated Photo Dy...Read More
(TheNewswire) Toronto, Ontario - TheNewswire - September 6, 2023 - Tantalex Lithium Resources Corp. (CSE:TTX) (FSE:DW8) (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to report it has filed an updated technical report titled “NI 43-101 Mineral Resourc...Read More
TORONTO, ON / ACCESSWIRE / August 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("...Read More
(TheNewswire) Toronto, Ontario – TheNewswire - August 28, 2023 – Tantalex Lithium Resources Corp. (CSE:TTX) – (FSE:DW8) – (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to announce the final tranche closing of its non-broker...Read More
(TheNewswire) Toronto, Ontario - TheNewswire - August 9, 2023 – Tantalex Lithium Resources Corp. (CSE:TTX) – (FSE:DW8) – (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to announce its majority owned subsidiary United Cominiere SAS...Read More
(TheNewswire) Toronto, Ontario - TheNewswire - August 2, 2023 - Tantalex Lithium Resources Corp. (CSE:TTX) (FSE:DW8) (OTC:TTLXF) (“Tantalex” or the “Corporation”), is is pleased to announce that at its Annual General Meeting of Shareholders, held on August 2, 2023, Tan...Read More
(TheNewswire) Toronto, Ontario - TheNewswire - July 21, 2023 - Tantalex Lithium Resources Corp. (CSE:TTX) (FSE:DW8) (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to announce a second tranche closing of a non-brokered private placement for gross proceeds of...Read More
(TheNewswire) Toronto, Ontario - TheNewswire - July 12, 2023 - Tantalex Lithium Resources Corp. (CSE:TTX) (FSE:DW8) (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to announce a first tranche closing of a non-brokered private placement for gross p...Read More
TORONTO, ON / ACCESSWIRE / June 30, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PD...Read More
(TheNewswire) Toronto, Ontario – TheNewswire - June 29, 2023 – Tantalex Lithium Resources Corp. (CSE:TTX) – (FSE:DW8) – (OTC:TTLXF) (“Tantalex” or the “Corporation”), is pleased to announce a non-brokered private placement consis...Read More
(TheNewswire) Toronto, Ontario – TheNewswire - June 7th, 2023 – Tantalex Lithium Resources Corp. (CSE:TTX) – (FSE:DW8) – (OTC:TTLXF) (“Tantalex” or the “Corporation”), activities in the DRC are in full speed as we are nearing com...Read More
TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs...Read More
TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs"...Read More
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release.TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TL...Read More
TORONTO, ON / ACCESSWIRE / May 24, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDC...Read More
For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator ("PI")) achieved a Complete Response ("CR") at any assessment date post primary Study Treatment and 30% of Evaluable Patients achieved a CR at 450 days.TORONTO, ON / ACCES...Read More